NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

JTORENCE,

Thanks for asking, but I couldn’t possibly know the answer to that—it’s a nonsensical question to ask why they’re not buying more and more while they’re already shareholders, but I’ll offer my speculation since you asked. What I do know is that they have a large number of shares already and seem to be holding for commercialization. Marketing the DCVax-L cell-based platform technology is one of the company’s stated goals.

I would also remind you that the CEO loaned NWBO millions from her own pocket to fund research into the DCVax-L technology. Of course, she was of rewarded for loaning her own money, but her actions were a testament to her confidence and her long-term commitment.

The CEO is holding 130 million shares, if I recall correctly.

I would guess that if large purchases were made by insiders during certain periods of time around the publication of the independent peer review, for example, or during the time preceding the MAA, those insiders could be accused of purchasing based on non-public information.

I also believe that their positions are already very large in proportion to their overall wealth. This inference is drawn from my own personal position in NWBO—I want to add shares at the current price, but my money is already invested. I’m already “maxed out” so to speak. I would buy more shares if I had the opportunity to add to my position. (I am a shareholder because I am interested in wealth and health—I look forward to the regulatory advisory reviews in multiple nations, and I personally hope to have access to an efficacious immunotherapy combo if I ever need treatment for cancer. I am neither an oncologist nor a financial advisor).

Let’s ask ChatGPT for more ideas:

There could be various reasons why a CEO might choose not to purchase stock in their own undervalued company, even if it's expected to rise. Some possible reasons include:

1. **Personal Financial Constraints:** The CEO may have personal financial constraints or commitments that limit their ability to invest in the company at that time.

2. **Regulatory Restrictions:** Legal or regulatory restrictions might prevent the CEO from buying or selling stock during specific periods, such as blackout periods around financial reporting.

3. **Ethical Considerations:** The CEO might want to avoid any perception of impropriety or conflict of interest, even if it's legally permissible, to maintain trust and transparency.

It's important to note that individual decisions can vary, and CEOs may have a combination of these or other reasons influencing their choices.
—ChatGPT

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847